Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 598

1.

Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the multicenter automatic defibrillator implantation trial II.

Goldenberg I, Moss AJ, Hall WJ, McNitt S, Zareba W, Andrews ML, Cannom DS; Multicenter Automatic Defibrillator Implantation Trial (MADIT) II Investigators.

Circulation. 2006 Jun 20;113(24):2810-7. Epub 2006 Jun 12.

2.

Efficacy of medical therapy for the reduction of heart failure events in patients with implanted cardioverter defibrillators.

Pietrasik G, Goldenberg I, McNitt S, Polonsky B, Moss AJ, Zareba W.

J Cardiovasc Electrophysiol. 2009 Apr;20(4):395-400. doi: 10.1111/j.1540-8167.2008.01333.x. Epub 2008 Oct 27.

PMID:
19017351
3.

Differences in outcomes between patients treated with single- versus dual-chamber implantable cardioverter defibrillators: a substudy of the Multicenter Automatic Defibrillator Implantation Trial II.

Berenbom LD, Weiford BC, Vacek JL, Emert MP, Hall WJ, Andrews ML, McNitt S, Zareba W, Moss AJ.

Ann Noninvasive Electrocardiol. 2005 Oct;10(4):429-35.

PMID:
16255753
4.

Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II.

Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML, Wilber DJ, Klein HU; MADIT-II Investigators.

J Am Coll Cardiol. 2006 May 2;47(9):1811-7. Epub 2006 Apr 17.

5.

Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator.

Moss AJ, Greenberg H, Case RB, Zareba W, Hall WJ, Brown MW, Daubert JP, McNitt S, Andrews ML, Elkin AD; Multicenter Automatic Defibrillator Implantation Trial-II (MADIT-II) Research Group.

Circulation. 2004 Dec 21;110(25):3760-5. Epub 2004 Dec 6.

6.

Risk stratification for primary implantation of a cardioverter-defibrillator in patients with ischemic left ventricular dysfunction.

Goldenberg I, Vyas AK, Hall WJ, Moss AJ, Wang H, He H, Zareba W, McNitt S, Andrews ML; MADIT-II Investigators.

J Am Coll Cardiol. 2008 Jan 22;51(3):288-96. doi: 10.1016/j.jacc.2007.08.058.

7.

Cost-effectiveness of implantable cardioverter-defibrillators.

Sanders GD, Hlatky MA, Owens DK.

N Engl J Med. 2005 Oct 6;353(14):1471-80.

8.

Mechanisms of death in the CABG Patch trial: a randomized trial of implantable cardiac defibrillator prophylaxis in patients at high risk of death after coronary artery bypass graft surgery.

Bigger JT Jr, Whang W, Rottman JN, Kleiger RE, Gottlieb CD, Namerow PB, Steinman RC, Estes NA 3rd.

Circulation. 1999 Mar 23;99(11):1416-21.

9.

Long-term benefit of primary prevention with an implantable cardioverter-defibrillator: an extended 8-year follow-up study of the Multicenter Automatic Defibrillator Implantation Trial II.

Goldenberg I, Gillespie J, Moss AJ, Hall WJ, Klein H, McNitt S, Brown MW, Cygankiewicz I, Zareba W; Executive Committee of the Multicenter Automatic Defibrillator Implantation Trial II.

Circulation. 2010 Sep 28;122(13):1265-71. doi: 10.1161/CIRCULATIONAHA.110.940148. Epub 2010 Sep 13.

10.

Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction.

Choy B, Hansen E, Moss AJ, McNitt S, Zareba W, Goldenberg I; Multicenter Automatic Defibrillator Implantation Trial-II Investigators.

Am J Cardiol. 2010 Mar 1;105(5):581-6. doi: 10.1016/j.amjcard.2009.10.041. Epub 2010 Jan 22.

PMID:
20185000
11.

Defibrillator implantation early after myocardial infarction.

Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, Kornacewicz-Jach Z, Sredniawa B, Lupkovics G, Hofgärtner F, Lubinski A, Rosenqvist M, Habets A, Wegscheider K, Senges J; IRIS Investigators.

N Engl J Med. 2009 Oct 8;361(15):1427-36. doi: 10.1056/NEJMoa0901889.

12.

Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator.

Barsheshet A, Moss AJ, Huang DT, McNitt S, Zareba W, Goldenberg I.

J Am Coll Cardiol. 2012 Jun 5;59(23):2075-9. doi: 10.1016/j.jacc.2012.02.036.

13.

Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum.

Bloomfield DM, Steinman RC, Namerow PB, Parides M, Davidenko J, Kaufman ES, Shinn T, Curtis A, Fontaine J, Holmes D, Russo A, Tang C, Bigger JT Jr.

Circulation. 2004 Oct 5;110(14):1885-9. Epub 2004 Sep 27.

14.

Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database.

Lee DS, Krahn AD, Healey JS, Birnie D, Crystal E, Dorian P, Simpson CS, Khaykin Y, Cameron D, Janmohamed A, Yee R, Austin PC, Chen Z, Hardy J, Tu JV; Investigators of the Ontario ICD Database.

J Am Coll Cardiol. 2010 Feb 23;55(8):774-82. doi: 10.1016/j.jacc.2009.11.029.

15.

Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design.

Raviele A, Bongiorni MG, Brignole M, Cappato R, Capucci A, Gaita F, Mangiameli S, Montenero A, Pedretti R, Salerno J, Sermasi S.

Am J Cardiol. 1999 Mar 11;83(5B):104D-111D.

PMID:
10089851
16.

Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.

Marijon E, Trinquart L, Otmani A, Waintraub X, Kacet S, Clémenty J, Chatellier G, Le Heuzey JY; Evaluation Médico-Economique du Défibrillateur Automatique Implantable (EVADEF) Investigators.

Am Heart J. 2009 Feb;157(2):391-397.e1. doi: 10.1016/j.ahj.2008.09.023. Epub 2008 Dec 3.

PMID:
19185651
17.

Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).

Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, Moss AJ; MADIT-II Investigators.

J Am Coll Cardiol. 2005 Nov 1;46(9):1712-20. Epub 2005 Oct 10.

18.

Predictors for short-term progressive heart failure death in New York Heart Association II patients implanted with a cardioverter defibrillator--the EVADEF study.

Marijon E, Trinquart L, Otmani A, Leclercq C, Fauchier L, Chevalier P, Klug D, Defaye P, Lellouche N, Mansourati J, Deharo JC, Sadoul N, Anselme F, Maury P, Davy JM, Extramiana F, Hidden-Lucet F, Probst V, Bordachar P, Mansour H, Chauvin M, Jouven X, Lavergne T, Chatellier G, Le Heuzey JY; EVADEF Investigators.

Am Heart J. 2010 Apr;159(4):659-664.e1. doi: 10.1016/j.ahj.2010.01.011.

PMID:
20362726
19.

Effect of elapsed time from coronary revascularization to implantation of a cardioverter defibrillator on long-term survival in the MADIT-II trial.

Barsheshet A, Goldenberg I, Moss AJ, Huang DT, Zareba W, McNitt S, Klein HU, Guetta V.

J Cardiovasc Electrophysiol. 2011 Nov;22(11):1237-42. doi: 10.1111/j.1540-8167.2011.02096.x. Epub 2011 May 26.

PMID:
21615813
20.

Predictors of appropriate implantable cardioverter-defibrillator therapy during long-term follow-up of patients with coronary artery disease.

Blumer J, Wolber T, Hellermann J, Holzmeister J, Binggeli C, Duru F, Brunckhorst C.

Int Heart J. 2009 May;50(3):313-21.

Supplemental Content

Support Center